anmelden
SPI
19.397,24
PKT
+66,03
PKT
+0,34
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SPI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 31.01.12 | Roche overweight | J.P. Morgan Cazenove | |
| 31.01.12 | ABB (Asea Brown Boveri) buy | Citigroup Corp. | |
| 31.01.12 | ABB (Asea Brown Boveri) outperform | Exane-BNP Paribas SA | |
| 31.01.12 | Nestlé kaufen | Hamburger Sparkasse AG (Haspa) | |
| 31.01.12 | ABB (Asea Brown Boveri) halten | Independent Research GmbH | |
| 31.01.12 | Novartis neutral | Goldman Sachs Group Inc. | |
| 31.01.12 | Nestlé outperform | Cheuvreux SA | |
| 31.01.12 | Zurich Insurance buy | Nomura | |
| 31.01.12 | Nestlé overweight | J.P. Morgan Cazenove | |
| 30.01.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 30.01.12 | Sulzer kaufen | Die Actien-Börse | |
| 30.01.12 | OC Oerlikon kaufen | Die Actien-Börse | |
| 30.01.12 | Barry Callebaut sell | Société Générale Group S.A. (SG) | |
| 30.01.12 | SGS SA neutral | Sarasin Research | |
| 27.01.12 | UBS underperform | Exane-BNP Paribas SA | |
| 27.01.12 | UBS underperform | Exane-BNP Paribas SA | |
| 27.01.12 | Holcim sell | Citigroup Corp. | |
| 27.01.12 | Logitech neutral | Citigroup Corp. | |
| 27.01.12 | Novartis outperform | Credit Suisse Group | |
| 27.01.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 26.01.12 | Roche overweight | Barclays Capital | |
| 26.01.12 | Zurich Insurance halten | Independent Research GmbH | |
| 26.01.12 | Logitech neutral | Sarasin Research | |
| 26.01.12 | Novartis underperform | Cheuvreux SA | |
| 25.01.12 | Roche outperform | Exane-BNP Paribas SA | |
| 25.01.12 | Holcim neutral | UBS AG | |
| 25.01.12 | Novartis buy | WestLB AG | |
| 25.01.12 | Novartis halten | Independent Research GmbH | |
| 25.01.12 | Novartis buy | Sarasin Research | |
| 25.01.12 | Lonza neutral | Sarasin Research | |
| 25.01.12 | SGS SA hold | Société Générale Group S.A. (SG) | |
| 24.01.12 | Kühne + Nagel International buy | Citigroup Corp. | |
| 24.01.12 | Roche buy | Deutsche Bank AG | |
| 24.01.12 | Novartis buy | Sarasin Research | |
| 24.01.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 23.01.12 | Zurich Insurance neutral | Exane-BNP Paribas SA | |
| 23.01.12 | Roche overweight | Barclays Capital | |
| 23.01.12 | Novartis buy | Nomura | |
| 20.01.12 | ams-OSRAM kaufen | Erste Bank AG | |
| 20.01.12 | Givaudan reduce | Nomura |
